Exogenous glucagon-like peptide-1 (GLP-1) attenuates the glycaemic response to small intestinal nutrient in the critically ill.
The effect of exogenous glucagon-like peptide-1 (GLP-1) compared to placebo on glycaemia in critically ill patients during small intestinal feeding
Adam Deane
8 participants
Jul 1, 2008
Interventional
Conditions
Summary
The primary objective of this study is to establish if glucagon-like peptide-1 (a hormone released from the gastrointestinal) has an effect on blood sugar levels in patients who are critically ill
Eligibility
Inclusion Criteria3
- Critically ill patients who require artificial ventilation
- Likely to be ventilated for >48hrs
- Suitable to receive enteral nutrition via naso-jejunal feeding tube
Exclusion Criteria7
- Age <18
- Age>85
- Pregnancy
- Small bowel obstruction
- History of diabetes
- Previous surgery on the oesophagus, stomoach or duodenum
- Any gastrointestinal surgery on this admission
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Glucagon-like peptide-1 at 1.2pmol.kg.min infused at 1ml/min between t=0-270min. Participants will cross-over to the other arm (i.e. GLP-1 to control and vice-versa) on the next consecutive day (as GLP-1 is rapidly metabolised with a t1/2 < 5mins)
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12609000093280